Table 1.

Anti-proliferative activities for hybrids 6a–i, 9a–f, and 11a,b against MCF-7 and MDA-MB-231 breast cancer cell lines.

Comp.	R	R1	R2	IC50 (µM)a
				MCF-7	MDA-MB-231
6a	H	H	-	3.12 ± 0.14	15.10 ± 0.73
6b	F	H	-	6.0 ± 0.32	6.36 ± 0.29
6c	Cl	H	-	2.72 ± 0.17	9.48 ± 0.44
6d	Br	H	-	3.31 ± 0.11	18.33 ± 0.71
6e	CH3	H	-	0.39 ± 0.05	22.54 ± 1.67
6f	OCH3	H	-	1.85 ± 0.08	2.85 ± 0.9
6g	OCF3	H	-	5.07 ± 0.21	7.19 ± 0.38
6h	NO2	H	-	21.40 ± 1.58	1.85 ± 0.07
6i	CH3	CH3	-	47.16 ± 3.02	NAb
9a	H	-	-CH3	5.50 ± 0.28	8.39 ± 0.27
9b	H	-	-CH2CH2CH3	40.89 ± 3.17	18.50 ± 0.85
9c	H	-	-CH2COOC2H5	67.51 ± 3.02	NAb
9d	H	-	-CH2C6H5	9.56 ± 0.61	6.50 ± 0.39
9e	H	-	-CH2C6H4-4-F	3.70 ± 0.19	1.03 ± 0.04
9f	Cl	-	-CH2CH2CH3	19.26 ± 0.65	9.44 ± 0.35
11a	-	-	-	84.70 ± 4.02	NAb
11b	-	-	-	NAb	NAb
Staurosporine	-	-	-	6.81 ± 0.22	10.29 ± 0.72

^a IC₅₀ values reported as the mean ± S.D. from 3 separate experiments, ^b NA: Hybrids possessing IC₅₀ more than 100 µM.